Eighty-two patients with small cell lung carcinoma refractory to standard chemotherapy were entered in this phase II randomized study of PALA, amsacrine, teniposide, and zinostatin. Of the 66 evaluable patients, one partial response occurred among 17 patients treated with teniposide and no responses occurred with the other drugs. Two patients each treated with amsacrine and teniposide experienced life-threatening hematologic toxic effects and one patient treated with zinostatin died of thrombocytopenic pulmonary hemorrhage. The overall median patient survival was 9.6 weeks. Weight loss ≥ 5% prior to therapy, extensive disease, and a nomambulatory status were associated with poor survival.
|Original language||English (US)|
|Number of pages||2|
|Journal||Cancer treatment reports|
|State||Published - 1984|
ASJC Scopus subject areas
- Cancer Research